Finance

Lists
NOT:ETR
Novartis AG
126,90 €
-0,36%
(-0,46) 1D
30-сен., 17:35:34 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOT...
Open
128,48 €
High
129,42 €
Low
126,68 €
Mkt. cap
288,77 млд
Avg. vol.
6,00 миң
Volume
3,95 миң
52-wk high
144,12 €
52-wk low
104,52 €
No. of employees
75 миң
Open
128,48 €
High
129,42 €
Low
126,68 €
Mkt. cap
288,77 млд
Avg. vol.
6,00 миң
Volume
3,95 миң
52-wk high
144,12 €
52-wk low
104,52 €
No. of employees
75 миң
News stories
From web sources and news partners
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75,3 миң
Founded1996-ж., 7-мар.
HeadquartersБазель, Базель-Штадт, Швейцария
SectorPharmaceutical industry
Last report
2026-ж., 21-июл.
Fiscal period
Q2 2026
EPS / Est. (USD)
2,41 USD / 2,15 USD
+12,21%beat
Revenue / Est. (USD)
14,95 млд / 14,06 млд
+6,36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
14,36 млд
13,86 млд
13,52 млд
14,95 млд
Cost of goods sold
3,54 млд
3,54 млд
3,44 млд
3,68 млд
Cost of revenue
3,54 млд
3,54 млд
3,44 млд
3,68 млд
Research and development expenses
2,86 млд
2,84 млд
2,78 млд
2,74 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,30 млд
3,44 млд
3,14 млд
3,23 млд
Operating expense
6,24 млд
6,46 млд
5,96 млд
6,10 млд
Total operating expenses
9,77 млд
10,00 млд
9,40 млд
9,78 млд
Operating income
4,58 млд
3,86 млд
4,12 млд
5,18 млд
Other non operating income
-7,00 млн
-130,00 млн
4,00 млн
19,00 млн
EBT including unusual items
4,20 млд
3,22 млд
3,84 млд
4,27 млд
EBT excluding unusual items
4,29 млд
3,49 млд
3,78 млд
4,73 млд
Income tax expense
266,00 млн
814,00 млн
683,00 млн
1,01 млд
Effective tax rate
6,34%
25,30%
17,79%
23,71%
Other operating expenses
70,00 млн
190,00 млн
42,00 млн
127,00 млн
Net income
3,93 млд
2,41 млд
3,16 млд
3,26 млд
Net profit margin
27,36%
17,38%
23,34%
21,83%
Earnings per share
2,25
2,03
1,99
2,41
Interest and investment income
-
373,00 млн
-
-
Interest expense
-281,00 млн
-304,00 млн
-343,00 млн
-462,00 млн
Net interest expenses
-281,00 млн
69,00 млн
-343,00 млн
-462,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
5,78 млд
4,96 млд
5,24 млд
6,30 млд
Gain or loss from assets sale
81,00 млн
80,00 млн
-159,00 млн
-247,00 млн
AI content may include mistakes. Learn more
Google колдонмолору